




FAIRVIEW

CAPITAL

INNOVATIVE. INTELLIGENT. INVESTMENTS.



City of New Haven
CONNECTICUT



June 17, 2020

Fairview Private Markets V, L.P.

Legal

The information set forth in this document is proprietary and shall be maintained in strict confidence. This document should not be distributed, published or reproduced in whole or in part, nor should its contents be disclosed by recipients to any other person.

This document is for informational purposes only and is not an offer to buy or sell, nor a solicitation of any offer to buy or sell any security or other financial instrument and may not be relied on in any manner as legal, tax or investment advice.

Prospective investors should make their own investigations and evaluations of the information contained in this document. Prior to closing of a private offering, Fairview Capital Partners, Inc. will give investors the opportunity to ask questions and receive additional information concerning terms and conditions of such offering and other relevant matters. Each prospective investor should consult its own legal, accounting and tax advisors as to legal, business, tax and related matters concerning the information contained in this document and such offering and in order to make an independent determination of the suitability and consequences of a potential investment.

Agenda

- ❖ Introduction to Fairview Capital
- ❖ Fairview's Venture Capital Program
- ❖ Appendix
 - Due Diligence Process, Monitoring, Compliance and ESG
 - Team Biographies
 - Other Fairview Data

Select Team Biographies



Kola Olofinboba
Managing Partner

- Joined Fairview in 2007
- Former consultant at McKinsey & Company
- Physician at the University of CT
- MBA in Financial Management from the MIT Sloan School of Management
- Medical degree from the University of Ibadan, Nigeria
- Board Member of Liberty Bank, Hartford HealthCare, CT Science Center and the National Association of Investment Companies (NAIC)



Alan I. Mattamana
Partner

- Joined Fairview in 2009
- Former Venture Capitalist with Polaris Partners
- Former consultant at McKinsey & Company
- B.Sc. Chemical Engineering, Princeton and MBA, Harvard
- Advisory Board of numerous venture capital and private equity funds
- Board Member of the Greater Hartford YMCA and The Hartford Foundation for Public Giving Board of Ambassadors



Michele Chow-Tai
Director and Head of Business Development

- Joined Fairview in 2015
- Former Relationship Manager, Institutional Relationships, at TIAA-CREF
- Former Assistant Director for the HSBC Financial Products Institute
- B.S., City University of New York
- FINRA 7 and 63 licensed
- Board chair for the City University of New York (CUNY) York College Foundation and Board Member for the National Association of Securities Professionals and Foundation - New York Chapter

Fairview Capital's Private Market Strategies Reflect the Future



We employ private market strategies that reflect the future by accessing areas where market intelligence, relationships, decision-making and nimbleness matter profoundly

We leverage our **diversity** and **inclusive culture** to build investment portfolios that reflect innovation and differentiation

Investments Driven By:

- **Innovation**
- Research
- **Diversity**

Fairview Provides Innovative Investment Solutions to Institutional Investors



Trusted
Investment
Advisor

- Independent, SEC registered, private equity investment management firm with aggregate fund capitalization of **\$9.7 billion*** since inception
- Manage **29** customized separate accounts and funds of funds on a discretionary basis



Disciplined
and Proven
Investment
Approach

- Extensive experience developing customized private equity solutions to help institutional investors successfully navigate complex market segments
- Proprietary time-tested programmatic approach to investing in the asset class



Experienced,
Cohesive
and Proven
Team

- Seasoned multi-generational cohesive team well positioned for the future
- Fully embedded in the private equity community - serving on **56** advisory boards
- Fully committed to providing institutional investors with superior risk-adjusted returns and the highest quality client service in the asset class

Fairview Has An Experienced, Diverse And Multi-Generational Team

The Fairview Capital Investment and Business Development Team



Laurence Morse

Co-Founder / Managing Partner
Venture/PE Experience: 36 Years
Prior: TSG Ventures, Equico Capital Corporation, UNC Ventures



Cynthia Tseng

Partner
Venture/PE Experience: 11 Years
Prior: JP Morgan Securities, Neutrogena Cosmetics



Michele Chow-Tai

Director and Head of Business Development
Venture/PE Experience: 10 Years
Prior: TIAA-CREF, HSBC



JoAnn Price

Co-Founder / Managing Partner
Venture/PE Experience: 39 Years
Prior: National Association of Investment Companies



Aakar Vachhani

Partner
Venture/PE Experience: 13 Years
Prior: Cambridge Associates, MK Capital



Lesley Nettles

Principal
Venture/PE Experience: 13 Years
Prior: Bank of America, Chase Asset Management



Kola Olofinboba

Managing Partner
Venture/PE Experience: 14 Years
Prior: McKinsey & Co., Physician - UConn Health Center



Kwesi Quaye

Senior Associate
Venture/PE Experience: 8 Years
Prior: Cook County Pension Fund, PWC, E&Y



Damaris Rivera

Senior Research Analyst and Business Development Coordinator
Venture/PE Experience: 15 Years
Prior: Hartford Medical Group, CT Multispecialty Group



Alan Mattamana

Partner
Venture/PE Experience: 18 Years
Prior: Polaris Venture Partners, McKinsey & Co.



Tré Dawson

Analyst
Venture/PE Experience: <1 Year
Prior: Chicago Fundamental Investment Partners, USDA



Ed Shirley

Senior Advisor
Venture/PE Experience: 35 Years
Prior: Advisory, Equitable Capital Management Corporation



Nicole Carey

Analyst
Venture/PE Experience: 1 Year
Prior: The Travelers Companies



The Fairview Team

- 12 investment professionals
- 14 finance, accounting and administrative professionals

Fairview Features An Experienced In-House Finance, Accounting And Compliance Team

The Fairview Capital Finance, Accounting and Compliance Team



Crystal Floyd

Chief Compliance Officer/ Corporate Controller

Venture/PE Experience: 15 Years
Prior: Pratt & Whitney



Peter Ruchwa

Controller - Fund Operations

Venture/PE Experience: 13 Years
Prior: The Hartford, United Healthcare



Ewa Koza

Corporate Accountant

Venture/PE Experience: 3 Years
Prior: Crowe Horwath LLP, Saslow Lufkin & Buggy LLP



John Barry

Senior Accountant

Venture/PE Experience: 30 Years
Prior: Bigler Investment Management Company



LaTasha Clark

Senior Accountant

Venture/PE Experience: 2 Years
Prior: Barings, LLC



Kelly Zerfass

Assistant Controller - Fund Operations

Venture/PE Experience: 12 Years
Prior: Deloitte & Touche



Michael Friedman

Accounting Manager

Venture/PE Experience: 11 Years
Prior: Rainbow USA, Goldburd & Loketch, LLP



Meredith Wilson

Accountant

Venture/PE Experience: 2 Years



Taury Del Valle

Accountant

Prior: GitlinCampisePrendergast, LLC
Venture/PE Experience: 1 Year



Diana Erha

HR Manager/Portfolio Accounting

Venture/PE Experience: 31 Years
Prior: Bigler Investment Management Company



Arlene Radke

Executive Assistant/Portfolio Accounting

Venture/PE Experience: 13 Years
Prior: Select Energy, Bank of America



Kelli Schaller

Executive Assistant/Portfolio Accounting

Venture/PE Experience: 16 Years
Prior: First New England Capital, LP



Christine Terwilliger

Administrative Assistant

Venture/PE Experience: 3 Years
Prior: Marriott Hotels



Nancy Burke

Receptionist/Administrative Assistant

Venture/PE Experience: < 1 Year
Prior: OneBeacon Insurance Company




Finance and Accounting Team and Infrastructure:

- Dedicated accounting professionals with CPAs and advanced degrees
- Comprehensive monitoring system
- Controlled financial reporting and valuation process
- Effective cash management system and forecasting
- Customized database maintained internally to analyze portfolio data
- In-house compliance program built internally
- Performance reporting


Fairview Has Been Built on a Vision for a Team Made Stronger by Diversity

An inclusive firm culture enables the potential of our cognitive diversity to drive results for our clients

Gender Diversity



Ethnic Diversity



- Diversity permeates the entire organization, starting with leadership and senior staff
- Fairview also actively seeks and works with diverse service providers (auditors, compliance, counsel etc.)

Fairview's Mission and Values Serve as Guiding Principles For The Firm's Approach to Sustainability and ESG

Organization

- Environmental impact is intentionally reduced through water and energy conservation, recycling and eco-friendly buildings
- Fairview is a leader in organizational diversity and culture
- Community service is a core value at Fairview
- Fairview's governance platform is built to best-in-class standards

Investments

- ESG considerations are incorporated into the due diligence process for investments
- During operational due diligence, Fairview examines ESG issues and policies
- Fairview will not partner with managers investing in: alcohol, drugs, guns /weapons, pornography and fossil fuels

Fairview maintains formal policies related to Sustainability and ESG including a formal ESG Policy, Compliance Manual, Code of Ethics and Employee Handbook

Fairview Offers A Range Of Private Equity Investment Solutions

Fairview's private equity investment solutions help institutional investors access and intelligently invest in demanding segments of the private equity market

Venture Capital/ Growth Equity

- Strategies range from seed/early-stage to late-stage/growth equity including direct co- investment
- Includes best in class, difficult to access managers as well as the next generation of leading venture capital managers

Next Generation

- Fairview defines next generation managers as newer funds, smaller funds, and diverse owned firms
- Strategies include: venture capital, small/mid-market buyout, mezzanine/sub-debt as well as direct co-investment

Co-Investments

- Resident direct venture capital investment expertise
- Leverages high-performing, multi-decade long venture investment program
- Perceived favorably by venture capital sponsors and by company management

Legacy Asset Management

- Fairview assumes day-to-day oversight of private equity funds
 - Customized relationship with services tailored based on the requested level of involvement
Oversight of all fund operations including fund accounting, audit and tax
-

Agenda

- ❖ Introduction to Fairview Capital
- ❖ Fairview's Venture Capital Program
- ❖ Appendix
 - Due Diligence Process, Monitoring, Compliance and ESG
 - Team Biographies
 - Other Fairview Data

Fairview Has Developed a Preeminent Venture Capital Program

21

Years of
Venture Investment
Experience

30

Sophisticated
Institutional
Clients

\$2.1B

Committed to
Venture Capital
Partnerships

193

Venture
Partnership
Investments

25+

Active
Venture Capital
Relationships



Intense Focus on Returns

Fairview venture partnerships have consistently outperformed industry benchmarks*



Access and Relationships

Exceptional access to best in class venture capital firms with meaningful levels of exposure



Distinct Ability to Successfully Identify Top Emerging Firms

Best-in-class venture capital and next generation manager programs active in tandem for 20+ years



Proven Processes: Research, Due Diligence and Manager Selection

Finely-tuned, proven processes - leveraging institutional memory and pattern recognition



Experienced and Diverse Team


Broad range of experience and perspectives brought to all of the firm's activities in the space



A Broad Base of Limited Partners have Invested with Fairview

Large and sophisticated institutional investors including Public Pensions: State, Municipal, Corporate Pensions, Universities, Retirement Systems, Endowments, Foundations, Family Offices and High Net Worth Individuals

Venture Capital is an Attractive Asset Class




Persistent Outperformance

Best in class venture capital firms have the ability to provide consistent outperformance relative to other venture capital firms as well as other asset classes over the long-term



Sustained Innovation

Sustained innovation will come from widespread applications of the current wave of technological disruption



Companies are Staying Private Longer

The best emerging companies are now staying private longer, shifting returns from the public markets to the private markets



Growth in Company Formation Provides High-Quality Deal Flow

Cost to launch companies is cheaper than ever and the rate of new company formation is increasing resulting in plentiful high-quality deal flow



Vital to Company Growth and Disruption

Venture capital remains critical to companies seeking to scale quickly at later stages as they fortify or establish themselves as category leaders in new and large markets



The Venture Capital Market Has Evolved

Many tenured firms have remained disciplined in their fund sizes and the most successful remain difficult to access for new investors - at the same time, new firms are employing novel approaches, many of which have the potential to outperform significantly

Fairview has a Specialized Approach to Investing in High Potential Venture Capital Funds



Funds with strong long-term track records - difficult to access

Novel and highly differentiated investment strategies - best in class teams

Top seed stage funds - must meet Fairview's criteria for institutional quality

Prior Investment Examples¹:



Prior Investment Examples¹:



Prior Investment Examples¹:



- Oversubscribed funds limit access to new LPs
- Allocations sought after by existing LPs

- Niche strategies also limit access to new LPs
- Investment programs without newer managers may lack funds that outperform

- Very large universe of (over 600) seed funds to select from
- Active involvement from early LPs required to aid institutionalization
- Limited capacity to absorb capital given small fund sizes

¹Select investments which Fairview considers to be representative of the strategy category. All investments are subject to due diligence process.

Fairview Has Significant Exposure to the Most Successful Companies in the Industry

Fairview has outsized exposure to the most successful VC-backed IPOs and Acquisitions...




Return Multiple for Select Exits*

10-20x

20-40x

40x+

...and the pipeline for future liquidity is robust



Last Round Post-Money Valuation**

\$1B+

\$5B+

\$20B+

*Gross return multiple on investment to Fairview funds of funds as of 12/31/2019. Data includes exited and partially exited companies.

**Last round post-money valuation as of December 2019. Source: Pitchbook

All return data, valuation data, and represented companies are across all Fairview managed funds

IPOs across all Fairview-managed funds (January 1, 2015 to December 31, 2019); a list of IPOs can be found in the Appendix

Note: List of all Fairview investments can be provided upon request

Fairview Produces Outsized Venture Capital Returns

	Net IRR	DPI	TVPI	Select Relationships
Fairview Ventures Fund III (2006)	14.2%	1.5x	2.3x	  
Fairview Constitution III (2007)	17.3%	1.7x	2.6x	   
Fairview Capstone Partners (2007)	18.3%	2.6x	3.1x	  
NY/Fairview EM Fund Tranche 2 (2008)	16.3%	1.1x	2.2x	   
Fairview Capstone Partners II (2008)	13.5%	1.3x	2.0x	   
Fairview Special Opportunities Fund (2011)	20.7%	0.7x	2.4x	   
Fairview Constitution IV (2012)	17.9%	0.6x	2.0x	    
Fairview Special Opportunities Fund II (2015)	19.8%	0.0x	1.6x	  
Constitution Fund V-A (2016)	19.6%	0.0x	1.4x	   
Fairview Private Markets Fund IV (2016)	6.6%	0.0x	1.1x	   

Subsequent Funds: Fairview Eversource Opportunity Fund (2018), Constitution Fund V-C (2018), Fairview Private Markets V (2019)

Performance data as of 12/31/2019

Note: Prior performance is not indicative of future returns

Net IRR performance figures based on cash flows and terminal values of each fund of funds. Returns are net of fees and expenses at both the partnership and fund of funds levels.

Data includes funds of funds established since 2006 with at least 50% of capital committed to venture capital partnerships.

Data excludes funds with performance data less than two years old (too young to have produced meaningful performance) and excludes special purpose funds Fairview Opportunity Fund and Fairview Volunteer Special Purpose Fund (2015).

Full track record available in Appendix.

Fairview is Raising Private Markets Fund V

Fairview is targeting \$200 million in commitments for Fairview Private Markets Fund V

Strategy

 Focus on best-in-class venture and growth equity managers with up to 20% in co-investments

 Investment strategies include:

- Venture
- Growth Equity

Segment	Potential Target Range	Strategies
Venture & Growth Equity Funds	80% - 100%	Early to late stage venture and growth equity
Co-investment and Secondaries	0% - 20%	

Implementation

 Diversification/Pacing:

- Commit \$200 million over a three-year period
- Target approximately 15-20 commitments in best in class partnerships
- Approximately equal-weighted

 Portfolio construction focused on appropriate investment stage and sector exposure

- Diversification can reduce the portfolio's overall risk profile

 Highly competitive fee structure

Fairview Private Markets Fund V Features A Healthy Pipeline

Fairview maintains a dynamic pipeline that is refreshed continuously to ensure that managers with distinctive returns are identified early and included appropriately

Approximate Timeline of Select Fairview Relationships

2019

2020

2021




Commitments made by Private Markets Fund V

* Due to confidentiality agreements Fairview cannot use this partnership's name on written marketing materials

Agenda

- ❖ Introduction to Fairview Capital
- ❖ Fairview's Venture Capital Program
- ❖ Appendix
 - Due Diligence Process, Monitoring, Compliance and ESG
 - Team Biographies
 - Other Fairview Data

Fairview's Fine-Tuned Due Diligence And Manager Selection Process



Environmental, Social and Governance Policy

Purpose

Fairview Capital Partners, Inc. (“Fairview” or the “Firm”) supports the principles for responsible investing on behalf of our investors and thus recognizes the importance of incorporating environmental, social and governance (“ESG”) considerations into our investment process to better manage risk and generate sustainable, long-term returns. Fairview will integrate analysis of financially material ESG issues of potential partnership portfolio company investments into Fairview’s investment making decisions. In keeping with its fiduciary responsibilities to its investors, Fairview manages its funds with the primary obligation of maximizing value. Fairview believes that the adoption of responsible investment policies and practices can improve long-term value for its investors, and the Firm recognizes that failure to identify, assess, and mitigate risks arising from these issues may significantly hinder or compromise investment performance.

Scope

This ESG policy applies to all investments made by Fairview Capital Partners, Inc., Fairview managed-funds and principals of the Firm.


Investment Process

Pre-Investment: It is the policy of Fairview to incorporate ESG considerations into the due diligence phase for all potential investments. Fairview’s robust due diligence and manager selection process gives the Firm comfort that it will consider the ESG risk and opportunities in the Firm’s investment making process. During the operational due diligence process, Fairview looks to ensure managers have given thought to ESG issues and whether they have established ESG policies. Information is documented for internal use within the operational due diligence questionnaires for each potential partnership investment. Fairview will utilize this information when responding to Limited Partner requests on ESG information.

Post-Investment: In order to ensure continued adherence to the Firm’s policy, it is the responsibility of the Fairview investment team to monitor the ESG initiatives made by the fund managers in which it invests. Issues should be evaluated in light of their ability to be remedied or improved and the potential harm to the reputation of the Firm and its investors. If a Fairview professional considers any issues to be significant, they shall report them to Fairview’s Investment Committee.

Seamless In-House Portfolio Management Platform

Fairview has a comprehensive monitoring system in place to track and understand each investment's development.



Our finance and analytics team performs a continuous process of comprehensive investment analysis and reporting.

Regulatory Compliance

Continuous Process of Rigorous Internal Controls and Risk Mitigation Procedures

Tone at the Top



Regulatory Environment

- Compliance with applicable laws and regulations
- Compliance Manual
- Code of Ethics
- Annual Training
- Resources: NSCP members, webinars, networking

SEC Filings/Controls

- Form ADV: Parts 1, Part 2 A&B
- Form PF
- Privacy Policy
- Risk Matrix Testing
- Annual compliance review
- CEO certification
- Independent consultant review
- Annual employee questionnaire

Fairview Has Proactively Responded To Changes In The Venture Capital Ecosystem

	Industry Trends		Fairview Response
Decreasing Valuations	<ul style="list-style-type: none"> • Repricing of private market assets • Most pronounced at the later stage 		<ul style="list-style-type: none"> • Continued focus on early stage • Back managers that successfully deployed capital across market cycles • Selectively pursue co-investments
Concentration of LP capital	<ul style="list-style-type: none"> • Successful managers raising larger pools of capital from LPs • Remote relationship building presenting challenges 		<ul style="list-style-type: none"> • Opportunity to deepen allocations to historically hard to access managers • Equal-weighted approach to portfolio construction
Rise Of Opportunity Funds	<ul style="list-style-type: none"> • Venture capital managers raising large, opportunity funds • Investing in follow-on rounds of successful companies 		<ul style="list-style-type: none"> • Seek to limit exposure to opportunity funds • Avoid teams that lack relevant late stage expertise
Rise Of Seed Funds	<ul style="list-style-type: none"> • Increase in investment activity at the earliest, seed stage • Dedicated seed stage funds institutionalizing 		<ul style="list-style-type: none"> • Very selectively access the most institutional-quality seed funds • Limit exposure but diversify across multiple managers
Generational Shifts	<ul style="list-style-type: none"> • Several venerable franchises undergoing generational shifts • Increased team-ups and spin-outs of premier talent 		<ul style="list-style-type: none"> • Build exposure to best-in-class franchises that are likely to thrive (e.g. Mayfield, Sierra, USVP) • Graduate top “next generation manager” brands into best-in-class venture portfolios (e.g. Emergence, Greycroft, Spark, Third Rock)



Fairview Capital's Complete Track Record (As of December 31, 2019)

Fund	Vintage	Commitment (\$M)	Net IRR	DPI	TVPI	Strategy
Constitution Fund V, LLC - Series C	2018	75.4	NM	NM	NM	Venture
Fairview Lone Star Fund II, L.P.	2018	30.3	NM	NM	NM	Emerging Manager
Fairview Eversource Opportunity Fund	2018	28.0	NM	NM	NM	Venture
Fairview Private Markets Fund IV, L.P.	2016	97.0	6.6%	0.0	1.1	Venture
Constitution Fund V, LLC - Series B	2016	20.1	8.9%	0.0	1.1	Venture
Constitution Fund V, LLC - Series A	2016	130.1	19.6%	0.0	1.4	Venture
LA Fire & Police Pension Plan*	2016	50.0	28.7%	0.0	1.4	Emerging Manager
Fairview Lone Star Fund, L.P.	2015	40.3	12.7%	0.0	1.3	Emerging Manager
Fairview Opportunity Fund, L.P.	2015	25.1	15.7%	0.1	1.5	Venture
Fairview Special Opportunities Fund II, L.P.	2015	87.4	19.8%	0.0	1.6	Venture
Fairview Volunteer Special Purpose Fund, L.P.	2015	25.0	16.9%	0.0	1.5	Venture
Lincoln Fund I, L.P.	2014	75.1	13.4%	0.2	1.4	Emerging Manager
Fairview Constitution IV, L.P.	2012	150.8	17.9%	0.6	2.0	Venture
Fairview Special Opportunities Fund, L.P.	2011	222.2	20.7%	0.7	2.4	Venture
Fairview Capstone Partners II, L.P.	2008	100.5	13.5%	1.3	2.0	Venture/Emerging
NY/Fairview Emerging Managers Fund, L.P. - Tranche 2	2008	85.9	16.3%	1.1	2.2	Venture/Emerging
Fairview Capstone Partners, L.P.	2007	100.5	18.3%	2.6	3.1	Venture/Emerging
Fairview Constitution III, L.P.	2007	301.5	17.3%	1.7	2.6	Venture/Emerging
Fairview Ventures Fund III, L.P.	2006	209.7	14.2%	1.5	2.3	Venture
NY/Fairview Private Equity Fund, L.P.	2006	19.2	5.4%	1.1	1.4	Emerging Manager
Fairview Constitution II, L.P.	2005	201.0	6.6%	1.4	1.6	Venture/Emerging
NY/Fairview Emerging Managers Fund, L.P.	2004	58.6	1.6%	1.0	1.1	Emerging Manager
Fairview Ventures Fund II - NY, L.P.	2003	100.5	7.1%	1.4	1.6	Venture
Fairview Ventures Fund II, L.P.	2003	120.6	4.1%	1.4	1.4	Venture
Fairview Ventures Fund I, L.P.	1999	290.3	3.2%	1.3	1.3	Venture

Performance data as of 12/31/2019

Note: Prior performance is not indicative of future returns

Net IRR based on cash flows and terminal values of each fund of funds. Returns are net of fees and expenses at both the partnership and fund of funds levels

Data does not include legacy asset management funds and funds in liquidation

Data excludes subsequent funds Constitution Fund V-D (2019), Fairview Private Markets Fund V (2019), Fairview Foundations Emerging Managers Fund (2019) and LA Fire & Police Pension Plan - Tranche 2 (2019).

NM - performance is too young to be meaningful

*LA Fire & Police Pension Plan represents a consulting contract in which Fairview sources and recommends investments, but does not hold assets for the client.

Fairview IPOs

January 1, 2015 - December 31, 2019

89Bio Ltd.	Crinetics Pharmaceuticals	Maxpoint Interactive, Inc.	scPharmaceuticals Inc.
10X Genomics, Inc.	CrowdStrike Holdings, Inc.	Mersana Therapeutics, Inc.	Selecta Biosciences, Inc.
Acacia Communications, Inc.	DataDog, Inc.	Milestone Pharmaceuticals, Inc.	SendGrid, Inc.
Adaptimmune Therapeutics plc	DocuSign	Mimecast	ShockWave Medical, Inc.
Adaptive Biotechnologies Corp.	Domo	MindBody, Inc.	Shopify
Aimmune Therapeutics, Inc.	Dropbox, Inc.	Mirna Therapeutics, Inc.	SiTime Corporation
Allakos, Inc.	Elasticsearch Global B.V.	Mirum Pharmaceuticals, Inc.	Slack Technologies, Inc.
Allena Pharmaceuticals, Inc.	Everspin Technologies, Inc.	MongoDB, Inc.	Smartsheet
Alteryx Analytics, Inc.	Fastly	MuleSoft, Inc.	SmileDirectClub LLC
Appian Corporation	FitBit	MyoKardia, Inc.	Snap, Inc.
Aprea AB	Fiverr International Ltd.	Natera	SolarEdge Technologies, Inc.
Aptinyx, Inc.	Flex Pharma, Inc.	Neuronetics	Spotify
Aquantia Corporation	ForeScout Tech, Inc.	NGM Biopharmaceuticals, Inc.	Square, Inc.
Arsanis, Inc.	Forty Seven	nLIGHT	Stitch Fix
Arvinas, Inc.	Fulcrum Therapeutics, Inc.	Nutanix Inc.	Sunrun Inc.
aTyr Pharma, Inc.	Galera Therapeutics, Inc.	Obalon Therapeutics, Inc.	Surface Oncology
Audentes Therapeutics, Inc.	Glaukos Corporation	Ooma, Inc.	Syndax Pharmaceuticals, Inc.
Avalara	Global Blood Therapeutics, Inc.	OpGen, Inc.	TELA Bio, Inc.
Axonics Modulation Technologies, Inc.	GoDaddy	Oportun	TelaDoc, Inc.
Beyondspring, Inc.	Guardant Health, Inc.	PagerDuty, Inc.	The RealReal, Inc.
Bill.com, Inc.	Homology Medicines, Inc.	Personalis, Inc.	Tintri, Inc.
Bloom Energy	Ideaya Biosciences, Inc.	PhaseBio Pharmaceuticals, Inc.	TRACON Pharmaceuticals
Blue Apron, Inc.	iHeartMedia, Inc.	PhaseRx	Trevi Therapeutics, Inc.
Blueprint Medicine	Impinj, Inc.	Phreesia, Inc.	Tricida
Box, Inc.	Inotek Pharmaceuticals, Inc.	Ping Identity Corporation	Twilio, Inc.
Carbon Black	Inspire Medical Systems	Pinterest Inc.	Uber Technologies, Inc.
Cardlytics, Inc.	Instructure, Inc.	Pluralsight	Unity Biotechnology
Cerecor Inc.	Invuity, Inc.	Principia Biopharma	Upwork Inc.
Chiasma, Inc.	iRhythm Technologies, Inc.	Proteostasis Therapeutics, Inc.	Vapotherm, Inc.
Cidara Therapeutics, Inc.	Jounce Therapeutics, Inc.	PURE Storage, Inc.	Xactly Corp
Cloudera, Inc.	Jumia	Ra Pharmaceuticals, Inc.	Xtera Communications, Inc.
CloudFlare, Inc.	Kala Pharmaceuticals, Inc.	Rapid7, Inc.	Yext, Inc.
Collegium Pharmaceuticals, Inc.	Liquidia Technologies	Redfin Corporation	Zoom Video Communications, Inc.
Colucid Pharmaceuticals, Inc.	Livongo Health, Inc.	REGENXBIO, Inc.	Zosano Pharma Corporation
Constellation Pharmaceuticals	Lyft, Inc.	Rhythm Pharmaceuticals, Inc.	Zscaler, Inc.
Coupa Software, Inc.	Magenta Therapeutics	Roku, Inc.	



Fairview Private Markets Fund V, L.P. Summary Of Principal Terms

The Fund:	Fairview Private Markets Fund V, L.P. (“FPMF V” or the “Fund”)
Offering:	Target \$200 million
Investment objectives:	Invest in high-quality venture capital and growth equity partnerships sponsored by 15 to 20 firms 20% of capital potentially allocated to co-investments/secondaries
Commitment Period:	Up to 48 months
General Partner:	Fairview PM Management V, LLC, whose members are the Firm’s partners
General Partner capital commitment:	0.5% of total investor commitments
Term:	Twelve years, subject to annual extensions in one year increments
Management fee:	0.75% over the initial term of the partnership
Carried Interest:	After Limited Partners have received distributions of 1.5x committed capital, carried interest of 4.0% on partnership investments and 10% on co-investments

Fairview Team Biographies



Laurence C. Morse, PhD, Co-founder/Managing Partner

Dr. Morse is a Co-founder and a Managing Partner at Fairview. Prior to co-founding Fairview, Dr. Morse held positions with TSG Ventures, Equico Capital Corporation and UNC Ventures. Dr. Morse serves on a number of advisory boards of venture capital partnerships including U.S. Venture Partners (USVP), Battery Ventures, Sierra Ventures and Trinity Ventures. He is a member of the boards of directors of Webster Financial Corporation (NYSE: WBS) and the Institute of International Education. He is also a member of the boards of trustees of Howard University (Vice Chair and Chair-elect) and Harris Associates Investment Trust (The Oakmark Mutual Funds). He is a former member of the board of directors of the Princeton University Investment Company, and a former member of the board of trustees of Princeton University. Dr. Morse graduated summa cum laude and Phi Beta Kappa from Howard University, having spent his junior year at The London School of Economics and Political Science as a Luard Scholar. He earned M.A. and Ph.D. degrees from Princeton University and has been a postdoctoral fellow at Harvard University.



Kolawole (Kola) Olofinboba, MD, Managing Partner

Dr. Olofinboba is a Managing Partner at Fairview and is involved in a broad set of investment, business development and governance activities at the firm. Additionally, he serves on the advisory boards of several private equity partnerships in Fairview's fund portfolios. Prior to joining Fairview, Dr. Olofinboba was an Engagement Manager at McKinsey & Company, serving U.S. and global clients in healthcare and private equity. He has also practiced medicine as a board-certified internist/hospitalist and assistant professor at the University of Connecticut Health Center in Farmington, CT. Dr. Olofinboba received his medical degree from the University of Ibadan, Nigeria and an MBA in Financial Management from the MIT Sloan School of Management, where he was a Robert Toigo Fellow. He serves on the boards of directors for Liberty Bank, Hartford HealthCare, the Connecticut Science Center, and the National Association of Investment Companies (NAIC).



JoAnn H. Price, Co-founder/Managing Partner

Ms. Price is Co-Founder and Managing Partner, a member of Fairview's investment committee and manager of all Fairview-sponsored funds. Prior to co-founding Fairview, Ms. Price served as president of the National Association of Investment Companies headquartered in Washington, D.C. Ms. Price serves on a number of national advisory committees and private equity advisory boards. Ms. Price is currently on the Howard University Board of Visitors and the YMCA of Greater Hartford Board of Trustees. Ms. Price is on the board of the Apollo Theater Foundation in New York City and is the former Chairperson of the Amistad Center for Art & Culture in Hartford, Connecticut. Ms. Price also serves as Chairperson of the Hartford Foundation for Public Giving and is on the Executive Committee of Trinity Health of New England. Ms. Price is a graduate of Howard University.

Fairview Team Biographies



Alan Mattamana, Partner

Mr. Mattamana is a Partner at Fairview Capital and a member of its Investment Committee. He is involved in investment selection, deal execution and monitoring activities for Fairview's venture capital and private equity partnership and direct co-investment portfolios. Mr. Mattamana serves on a number of advisory boards of venture capital and private equity partnerships, and represents Fairview on direct investments including eVariant (acquired by Healthgrades), R4 Technologies, Device42, and Covr Financial.

Prior to joining Fairview in 2009, Mr. Mattamana was a Principal with Polaris Venture Partners, a diversified venture capital firm with over \$3.5 billion under management. He joined Polaris in 2002 and focused on venture capital investments in the software, digital media, consumer, medical technology, and healthcare services sectors. He was involved in several successful investments including Q1 Labs, Archivas and Turbine Entertainment, and served as board observer to portfolio companies including Advion BioSciences and GI Dynamics. Previously, Mr. Mattamana was a strategy consultant at McKinsey & Co, where he served clients in the software, telecommunications and aerospace sectors in the firm's Silicon Valley office. He also has prior experience at NASA, Goldman Sachs, and Neuberger Berman. Mr. Mattamana graduated from Princeton University with a B.S.E in Chemical Engineering, and earned an MBA from Harvard Business School. He serves on the Greater Hartford YMCA Board of Directors and The Hartford Foundation for Public Giving Board of Ambassadors, and is a former member of the Board of Directors of the Hartford Stage Theatre.



Cynthia Tseng, Partner

Ms. Tseng is a Partner and a member of Fairview's investment committee. She is involved in research, due diligence, investment monitoring, and business development for Fairview's venture capital and private equity partnership and direct co-investment portfolios. Prior to joining Fairview, she was an investment banking associate at JPMorgan. Ms. Tseng joined JPMorgan in 2000 and focused on convertible bond and equity origination in the retail, media and chemical industries. There, she structured and executed capital raising transactions for Fortune 500 companies. For a portion of her career at JPMorgan, Ms. Tseng covered aerospace companies in equity research with a top ranked Institutional Investor Analyst. Ms. Tseng also has prior experience at Neutrogena Cosmetics - Johnson & Johnson as a brand management intern.

Ms. Tseng received her MBA from The Wharton School at the University of Pennsylvania. She holds a B.A. in Applied Mathematics/ Economics from Brown University and graduated Phi Beta Kappa. Ms. Tseng is a CFA charter holder and a member of the Hartford CFA Society. She is a member of the board of directors of The Association of Asian American Investment Managers (AAAIM), Hartford Performs and The Connecticut Health Foundation.



Aakar Vachhani, Partner

Mr. Vachhani, who joined the Firm in 2008, is a Partner and a member of Fairview's investment committee. He is involved in research, due diligence, investment monitoring, and business development for Fairview's venture capital and private equity partnership and direct co-investment portfolios. Prior to joining Fairview, Mr. Vachhani was with Cambridge Associates, a leading investment advisor to foundations, endowments and corporate and government entities. He was responsible for analyzing private equity, venture capital, and real estate funds in support of the firm's clients and consultants. In addition, he led quantitative research projects on private equity and venture capital returns. Mr. Vachhani also spent time with MK Capital, a multi-stage growth equity and venture capital firm.

Mr. Vachhani holds a B.S. in Economics-Finance from Bentley University and an MBA in Finance and Entrepreneurship & Innovation from the Kellogg School of Management. He is a member of the Board of Directors of San Francisco Achievers. Mr. Vachhani established and leads Fairview's San Francisco office.

Fairview Team Biographies



Michele A. Chow-Tai, Director and Head of Business Development

Ms. Chow-Tai is Director and Head of Business Development at Fairview. Prior to joining Fairview in 2015, Ms. Chow-Tai was Relationship Manager, Institutional Relationships, at TIAA, where she was responsible for leading client relationships with the company's largest and most complex clients across business disciplines. Prior to TIAA, Ms. Chow-Tai spent 22 years within HSBC's Global Banking and Markets business in various roles. Ms. Chow-Tai spent 22 years within HSBC's Global Banking and Markets in various roles working with institutional investors across asset classes and business lines. Ms. Chow-Tai also served as Assistant Director for the HSBC Financial Products Institute, a division focused primarily on derivatives and structured products client education. Prior to HSBC, Ms. Chow-Tai spent five years at Moody's Investor Services as bank and finance analyst.

Ms. Chow-Tai serves as Board Chair for the City University of New York (CUNY) York College Foundation and Board Member and Secretary of the National Association of Securities Professionals - New York Chapter (NASP-NY) and Board Member of the NASP-NY Foundation. Ms. Chow-Tai also serves on the Advisory Board of LeaderXXchange, a purpose driven organization that advises and promotes diversity and sustainability in governance, leadership and investments. Ms. Chow-Tai holds a B.S. degree from the City University of New York - York College and also holds credentials in business administration and finance. Ms. Chow-Tai has passed the FINRA 7 and 63 NASD exams.



Lesley D. Nettles, Principal

Ms. Nettles is a member of Fairview's investment team. Prior to joining Fairview in 2006, Ms. Nettles held business development positions within two of Bank of America's asset management subsidiaries. Most recently, Ms. Nettles was a Director for Columbia Management Group where she developed the firm's national Public Fund business strategy. As a VP at Progress Investment Management Company, Ms. Nettles primarily focused on the Western Region of the U.S. with a secondary focus on select plan sponsors across the nation. In both roles, she participated as a member of senior strategy and investment committee meetings.

Ms. Nettles also held VP roles at Lend Lease Real Estate Investment, Inc. and Chase Asset Management. In both roles, she worked directly with senior management to design and execute a global business development plan.

Ms. Nettles holds a B.A. from University of California at Berkeley. She holds a Real Estate Certification from Georgia State/Lend Lease University. Ms. Nettles is on the Board for the National Association of Securities Professionals, New York Chapter and Complexions Dance Company.



Kwesi Quaye, Senior Associate

Mr. Quaye joined Fairview in 2017 and is a member of the Investment Team. He focuses on research, due diligence, deal sourcing, investment monitoring, and business development for Fairview's venture capital and private equity partnership and direct co-investment portfolios. Prior to joining Fairview, Mr. Quaye was an Investment Officer at the Cook County Pension Fund, where he supported portfolio strategy across all asset classes. Additionally, in that role, Mr. Quaye led investment manager due diligence and performed various portfolio optimization analyses to maximize risk-adjusted returns. Mr. Quaye also spent time with PricewaterhouseCoopers LLP where he served as a Senior Transaction Advisory Associate performing buy-side mergers and acquisitions due diligence on companies in the healthcare, education, and consumer products spaces. Moreover, Mr. Quaye also spent time with Ernst & Young LLP as a Senior Associate in the Assurance practice where he led day to day audit engagements for diversified services clients. Mr. Quaye holds a B.S. with concentrations in Accounting and Finance from DePaul University and an MBA in Finance and Management & Strategy from the Kellogg School of Management at Northwestern University. He is the Chairman of the West Hartford & Tri-Town YMCA Board of Advisors.

Fairview Team Biographies



Damaris Rivera, Senior Research Analyst and Business Development Coordinator

Ms. Rivera joined Fairview in 2004 and is a member of the Business Development team. She focuses on activities that support the firm's investor relations. In addition, she performs investor research, tracks business activities, generates and prepares marketing materials, coordinates schedules with external and internal participants and facilitates the planning for conferences, meetings and other related events. Prior to Ms. Rivera's current role, she served as Operations Analyst where she was responsible for analyzing and summarizing the financial information of the firm's private equity funds and conducting other administrative duties. Prior to joining Fairview, Ms. Rivera was a Medical Receptionist at the Hartford Medical Group and Emergency Room Admitting Clerk at New Britain General Hospital.

Ms. Rivera holds a B.S. in Business Management and graduated Magna Cum Laude from Albertus Magnus College. She is also a Notary Public.



Tré Dawson, Analyst

Mr. Dawson joined Fairview in 2019, after interning with the Firm, and is a member of the Investment Team. He focuses on research, due diligence, deal sourcing, investment monitoring, and business development for Fairview's venture capital and private equity partnership and direct co-investment portfolios. Prior to joining Fairview, Mr. Dawson also interned with the United States Department of Agriculture and Chicago Fundamental Investment Partners, both in financial services capacities.

Mr. Dawson is a recent honors graduate of Howard University, with a Bachelor of Business Administration degree .



Nicole Carey, Analyst

Ms. Carey joined Fairview in 2020 after interning with the Firm and is a member of the Investment Team. She focuses on research, due diligence, deal sourcing, investment monitoring, and business development for Fairview's venture capital and private equity partnership and direct co-investment portfolios. Prior to joining Fairview, Ms. Carey interned with Travelers as part of their Financial Management Leadership Development Program.

Ms. Carey is a recent honors graduate of Central Connecticut State University, with a B.S. in Finance.

Fairview Team Biographies



Edwin S. Shirley III, Senior Advisor

Mr. Shirley is a senior advisor to the firm. Prior to joining Fairview in 1998, Mr. Shirley was a principal in several investment advisory firms where he was responsible for the design and placement of private debt and equity securities for small and middle-market companies. Mr. Shirley began his investment career at Equitable Capital Management Corporation where he successfully invested in private debt and equity securities across a broad range of industries.

Mr. Shirley serves on the advisory boards of several Fairview partnership funds. Additionally, he is a member of the Board of Directors of Milestone Growth Fund, a Minneapolis based mezzanine and private equity fund, The Amistad Center for Art & Culture, the Hartford Symphony Orchestra and the Bushnell Center for the Performing Arts.

Mr. Shirley holds a Bachelor of Arts degree from Hampton University and a Master of Public Affairs degree from the Woodrow Wilson School of Public and International Affairs, Princeton University.